Investigating the effect of mesenchymal stem cells of deciduous tooth pulp on regeneration of the hematopoietic system after hematopoietic stem cell transplantation

Study of the effect of intravenous injection of Deciduous dental pulp mesenchymal stem cell in hematopoietic stem cell engraftment after autologus hematopoietic stem cell transplantation (HSCT) in patients with Hodgkin and non-Hodgkin Lymphoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140911019125N10

Enrollment

Registered

2024-05-29

Start date

2024-08-22

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Outcomes after autologous hematopoietic stem cell transplantation. Other disorders of blood and blood-forming organs in diseases classified elsewhere

Interventions

Intervention 1: Intervention group: In the first intervention group, after the selection of the patient, a sample of mesenchymal stem cells from the deciduous tooth pulp will be injected intravenously

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients aged between 18 and 70 years Patients with Hodgkin's and non-Hodgkin's lymphomas who are candidates for autologous bone marrow transplantation Not having uncontrollable infections, liver, kidney, lung and heart problems based on transplant criteria

Exclusion criteria

Exclusion criteria: Patients with uncontrollable infection Patients who are serologically positive for HIV and HTLV-1, HBV, HCV. Patients with coronary artery insufficiency, recent myocardial infarction, patients with recent manifestations of heart failure Patients with renal failure and urinary tract obstruction Patients with a history of sensitivity to conditioning chemotherapy drugs Patient dissatisfaction

Design outcomes

Primary

Measure	Time frame
Investigating the rate of regeneration of white blood cells. Timepoint: daily until discharge from the hospital. Method of measurement: Counting with a blood cell counter.;Investigating the regeneration rate of platelets. Timepoint: daily until discharge from the hospital. Method of measurement: Counting with a blood cell counter.;Checking the increase in hemoglobin. Timepoint: daily until discharge from the hospital. Method of measurement: with blood cell counter.	—

Measure

Time frame

Investigating the rate of regeneration of white blood cells. Timepoint: daily until discharge from the hospital. Method of measurement: Counting with a blood cell counter.;Investigating the regeneration rate of platelets. Timepoint: daily until discharge from the hospital. Method of measurement: Counting with a blood cell counter.;Checking the increase in hemoglobin. Timepoint: daily until discharge from the hospital. Method of measurement: with blood cell counter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Farsinejad

Kerman University of Medical Sciences

afarsinejad@kmu.ac.ir+98 34 3132 5374

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026